Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Nebius Group NV (NBIS) Price & Performance

AbCellera Biologics IncTrade
Nebius Group NVTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Nebius Group NV — how do they compare? AbCellera Biologics Inc trades at $9.99 (market cap $2.99B), while Nebius Group NV trades at $249.84 (market cap $49.06B). The key difference: Nebius Group NV is far larger — about 16.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.

ABCLNBIS
Market Cap
$2.99B$49.06B
Sector
HealthTechnology
52-Week High
$9.76$286.69
52-Week Low
$2.78$64.06
Enterprise Value
$2.58B$49.26B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Nebius Group NV

NBIS stock trades at $249.82, up 35.69% in 24 hours, driven by strong Q2 2026 earnings beats and positive AI cloud demand sentiment. Technicals are bearish with key support at $190 and resistance at $196, while fundamentals show rapid revenue growth but negative EPS and high valuation multiples. Recent news highlights Michael Burry's short position alongside upbeat analyst coverage.

Outlook is mixed: high growth in AI infrastructure offers upside, but execution risks, negative earnings, and stretched valuations pose significant challenges. Analyst consensus is bullish with an $248.73 price target, yet competitive pressures and capital intensity require careful monitoring for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

Read more on NBIS